Oral Lichenoid Drug Eruption: A Report of a Pediatric Case and Review of the Literature
Victoria Woo D.D.S.,
Julia Bonks D.M.D.,
Lyubov Borukhova D.M.D.,
David Zegarelli D.D.S.,
Victoria Woo D.D.S.
School of Dental Medicine, University of Nevada, Las Vegas, Nevada
Search for more papers by this authorJulia Bonks D.M.D.
Columbia University College of Dental Medicine, New York, New York
Search for more papers by this authorLyubov Borukhova D.M.D.
Columbia University College of Dental Medicine, New York, New York
Search for more papers by this authorDavid Zegarelli D.D.S.
Columbia University College of Dental Medicine, New York, New York
Search for more papers by this authorVictoria Woo D.D.S.,
Julia Bonks D.M.D.,
Lyubov Borukhova D.M.D.,
David Zegarelli D.D.S.,
Victoria Woo D.D.S.
School of Dental Medicine, University of Nevada, Las Vegas, Nevada
Search for more papers by this authorJulia Bonks D.M.D.
Columbia University College of Dental Medicine, New York, New York
Search for more papers by this authorLyubov Borukhova D.M.D.
Columbia University College of Dental Medicine, New York, New York
Search for more papers by this authorDavid Zegarelli D.D.S.
Columbia University College of Dental Medicine, New York, New York
Search for more papers by this authorAddress correspondence to Victoria Woo, D.D.S., Columbia University—Division of Oral Pathology, 630 W. 168th Street, PH15W-1562 New York, NY 10032, or e-mail: [email protected].
Abstract
Abstract: Lichenoid drug eruptions are seen most frequently on the skin and seldomly affect the mucosal surfaces. Oral involvement—known as oral lichenoid drug eruption—is more common in the adult population and has been associated with numerous medications. Pediatric-onset oral lichenoid drug eruption is an exceptionally rare finding with only isolated cases published in the literature. The nonspecific appearance and latent presentation of pediatric oral lichenoid drug eruption can cause confusion in diagnosis and treatment. We report a case of oral lichenoid drug eruption occurring in a 15-year-old and explore challenges in the clinical and histologic recognition of this condition.
References
- 1 Boyd AS, King LE. Lichenoid drug reaction from isotretinoin therapy. Cutis 2001; 68: 301–303.
- 2 Kaur S, Bhalla M, Thami GP. Subacute lichenoid eruption due to L-thyroxine overdosage. Dermatology 2003; 206: 346–347.
- 3 Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med 2004; 15: 221–239.
- 4 Korstanje MJ. Drug-induced mouth disorders. Clin Exp Dermatol 1995; 20: 10–18.
- 5 McCartan BE, McCreary CE. Oral lichenoid drug eruptions. Oral Dis 1997; 3: 58–63.
- 6 Günes AT, Fetil E, Ilknur T et al. Naproxen-induced lichen planus: report of 55 cases. Int J Dermatol 2006; 45: 709–712.
- 7 Tilly JJ, Drolet BA, Esterly NB. Lichenoid eruptions in children. J Am Acad Dermatol 2004; 51: 606–624.
- 8 Neville BW, Damm DD, Allen CM et al. Allergies and immunologic diseases. In: BW Neville, DD Damm, CM Allen, JE Bouquot, eds. Oral & maxillofacial pathology, 2nd edn. New York: W.B. Saunders Company, 2002: 300–303.
- 9 Hay KD, Reade PC. Methyldopa as a cause of oral mucous membrane reactions. Br Dent J 1978; 145: 195–203.
- 10 Wiesenfeld D, Scully C, MacFadyen EE. Multiple lichenoid drug reactions in patients with Ferguson-Smith disease. Oral Surg Oral Med Oral Pathol 1982; 54: 527–529.
- 11 Lamey PJ, McCartan BE, MacDonald DG et al. Basal cell cytoplasmic autoantibodies in oral lichenoid reactions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79: 44–49.
- 12 Robinson NA. Lichenoid tissue reactions of the oral mucosa. Singapore Dent J 2000; 23(Suppl. 1): 56–63.
- 13 Campisi G, Florena AM, Franco V et al. Oral lichenoid drug reaction by lithium in a patient with bipolar disorder. J Oral Pathol Med 2005; 34: 124–126.
- 14 Potts AJ, Hamburger J, Scully C. The medication of patients with oral lichen planus and the association of nonsteroidal anti-inflammatory drugs with erosive lesions. Oral Surg Oral Med Oral Pathol 1987; 64: 541–543.
- 15 Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica 1989; 179: 10–13.
- 16 Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993; 29(2 pt 1): 249–255.
- 17 McCartan BE, McCreary CE, Healy CM. Studies of drug-induced lichenoid reactions: criteria for case selection. Oral Dis 2003; 9: 163–164.
- 18 Zelickson BD, Rogers RS III. Drug reactions involving the mouth. Clin Dermatol 1986; 4: 98–109.
- 19 Van Beek MJ, Piette WW. Antimalarials. Dermatol Clin 2001; 19: 147–160.
- 20 Hawk JLM. Lichenoid drug eruption induced by propanolol. Clin Exp Dermatol 1980; 5: 93–96.
- 21 Robertson WD, Wray D. Ingestion of medication among patients with oral keratoses including lichen planus. Oral Surg Oral Med Oral Pathol 1992; 74: 183–185.
- 22 Breathnach S. Drug reactions. In: T Burns, S Breathnach, N Cox, C Griffiths, eds. Rook’s textbook of dermatology, Vol. 4, 7th edn. Oxford: Blackwell Science, 2004: 1–180.
- 23 Firth NA, Reade PC. Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions. Oral Surg Oral Med Oral Pathol 1989; 67: 41–44.
- 24 Hamburger J, Potts AJ. Non-steroidal anti-inflammatory drugs and oral lichenoid reactions. Br Med J (Clin Res Ed) 1983; 287: 1258.
- 25 Bagán JV, Thongprasom K, Scully C. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib. Oral Dis 2004; 10: 401–403.
- 26 Scully C, Diz Dios P. Orofacial effects of antiretroviral therapies. Oral Dis 2001; 7: 205–210.
- 27 Ficarra G, Flaitz CM, Gaglioti D et al. White lichenoid lesions of the buccal mucosa in patients with HIV infection. Oral Surg Oral Med Oral Pathol 1993; 76: 460–466.
- 28 Büyükgebiz B, Arslan N, Ostürk Y et al. Drug reaction to ursodeoxycholic acid: lichenoid drug eruption in an infant using ursodeoxycholic acid for neonatal hepatitis. J Pediatr Gastroenterol Nutr 2002; 35: 384–386.
- 29 Ridola V, Mahé E, Fawaz O et al. Dactinomycin-induced severe lichenoid eruption in a child. Pediatr Dermatol 2006; 23: 503–506.
- 30 Kanwar VS, Gajjar A, Ribeiro RC et al. Unusual cutaneous toxicity following treatment with dactinomycin: a report of two cases. Med Pediatr Oncol 1995; 24: 329–333.
- 31 Parks ET. Lesions associated with drug reactions. Dermatol Clin 1996; 14: 327–337.
- 32 Wright JM. Oral manifestations of drug reactions. Dent Clin North Am 1984; 28: 529–543.
- 33
Tack DA,
Rogers RS.
Oral drug reactions.
Dermatol Ther
2002; 15: 236–250.
10.1046/j.1529-8019.2002.01532.x Google Scholar
- 34 Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. Australas J Dermatol 2006; 47: 57–59.
- 35 Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol 1998; 16: 325–332.
- 36 Al-Hashimi I, Schifter M, Lockhart PB et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(Suppl. 1): S25–S31.
- 37 Felder RS, Millar SB, Henry RH. Oral manifestations of drug therapy. Spec Care Dentist 1988; 8: 119–124.
- 38 Usman A, Kimyai-Asadi A, Stiller MJ et al. Lichenoid eruption following hepatitis B vaccination: first North American case report. Pediatr Dermatol 2001; 18: 123–126.
- 39 Agrawal S, Garg VK, Joshi A et al. Lichen planus after HBV vaccination in a child: a case report from Nepal. J Dermatol 2000; 27: 618–620.
- 40 Limas C, Limas CJ. Lichen planus in children: a possible complication of hepatitis B vaccines. Pediatr Dermatol 2002; 19: 204–209.
- 41 Cottoni F, Ena P, Tedde G et al. Lichen planus in children: a case report. Pediatr Dermatol 1993; 10: 132–135.
- 42 Kanwar AJ, Handa S, Ghosh S et al. Lichen planus in childhood: a report of 17 patients. Pediatr Dermatol 1991; 8: 288–291.
- 43 Kumar V, Garg BR, Baruah MC et al. Childhood lichen planus (LP). J Dermatol 1993; 20: 175–177.
- 44 Sharma R, Maheshwari V. Childhood lichen planus: a report of fifty cases. Pediatr Dermatol 1999; 16: 345–348.
- 45 Nanda A, Al-Ajmi HS, Al-Sabah H et al. Childhood lichen planus: a report of 23 cases. Pediatr Dermatol 2001; 18: 1–4.
- 46 Alam F, Hamburger J. Oral mucosal lichen planus in children. Int J Paediatr Dent 2001; 11: 209–214.
- 47 Winer LH, Leeb AJ. Lichenoid eruptions. a histopathological study. AMA Arch Derm Syphilol 1954; 70: 274–281.
- 48 Beckman KA, Chanes L, Kaufman SR. Lichen planus associated with topical beta-blocker therapy. Am J Opthalmol 1995; 120: 530–531.
- 49 Powell ML, Ehrlich A, Belsito DV. Lichenoid drug eruption to salsalate. J Am Acad Dermatol 2001; 45: 616–619.
- 50 Schiødt M. Oral lupus erythematosus. III. A histopathologic study of sixty-six patients. Oral Surg Oral Med Oral Pathol 1984; 57: 281–293.
- 51 Helander SD, Rogers RS III. The sensitivity and specificity of direct immunofluorescence testing in disorders of mucous membranes. J Am Acad Dermatol 1994; 30: 65–75.
- 52 Van Joost T. Incidence of circulating antibodies reactive with basal cells of skin in drug reactions. Acta Derm Venereol Suppl (Stockh) 1974; 54: 183–187.
- 53 McQueen A, Behan WMH. The ‘string of pearls’ phenomenon – an immunofluorescent serological finding in patients screened for adverse drug reactions. Am J Dermatopathol 1982; 4: 155–159.
- 54 Kurumaji Y, Miyazaki K. Tiopronin-induced lichenoid eruption in a patient with liver disease and positive patch test reaction to drugs with sulfhydryl group. J Dermatol 1990; 17: 176–181.
- 55 Sharma VK, Vatve M, Sawhney IM et al. Clinical spectrum of drug rashes due to antiepileptics. J Assoc Physicians India 1998; 46: 595–597.
- 56 Penneys NS, Ackerman AB, Gottlieb NL. Gold dermatitis. Arch Dermatol 1974; 109: 372–376.
- 57 Savage NW. Oral lichenoid drug eruptions. Oral Dis 1997; 3: 55–57.
- 58 Lozada-Nur FI, Sroussi HY. Tacrolimus powder in Orabase 0.1% for the treatment of oral lichen planus and oral lichenoid lesions: an open clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 744–749.
- 59 Dalmau J, Peramiquel L, Puig L et al. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol 2006; 154: 1213–1216.
- 60 Thomson Healthcare, Inc. Physician’s desk reference, 59th ed. New Jersey: Thomson Healthcare, Inc., 2005. p. 1742–1747, 2377–2380.
- 61 Roberts DL, Marks R. Skin reactions to carbamazepine. Arch Dermatol 1981; 117: 273–275.
- 62 Atkin SL, Mckenzie TM, Stevenson CJ. Carbamazepine-induced lichenoid eruption. Clin Exp Dermatol 1990; 15: 382–383.
- 63 Jain KK. Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy. Drug Saf 1991; 6: 350–360.
- 64 Simpson JR. “Collagen disease” due to carbamazepine (Tegretol). Br Med J 1966; 2: 1434.
- 65 Shuttleworth D, Graham-Brown RA. Fixed drug eruption due to carbamazepine. Clin Exp Dermatol 1984; 9: 424–426.
- 66 Goldstein S. Is ADHD a growth industry. J Atten Disord 2006; 9: 461–464.
Citing Literature
